Propranolol Drug

Propranolol Drug

Propranolol is a medication that is used to treat a variety of conditions, such as high blood pressure, heart arrhythmias, anxiety, and migraines. It Propranolol is a nonselective β-adrenergic receptor antagonist. Blocking these receptors induces endothelial cell apoptosis as vasoconstriction, inhibition of angiogenic factors such as vascular endothelial growth factor (VEGF) and basal fibroblast growth factor (bFGF), and downregulation of vascular endothelial cells. happens. renin-angiotensin-aldosterone system. The increasing incidence of cardiovascular diseases and the growing demand for effective treatments for hypertension are the primary factors driving the market for propranolol drugs. For instance, as per the World Health Organization, in 2021, Cardiovascular disease (CVD) is the leading cause of death worldwide, claiming an estimated 17.9 million lives each year.

Propranolol Drug Market is expected to grow at a strong CAGR of 4% during the forecast period owing to increasing research efforts on the propranolol drug. For instance, National Cancer Institute (NCI) conducted a study of propranolol for the treatment of Kaposi Sarcoma in children and adults. This study will be an open-label single-armed treatment trial that will test the effectiveness and safety of treating Kaposi Sarcoma with propranolol.

• Based on application, the market is segmented into hypertension, angina, heart rhythm management, and others. As per our analysis, the hypertension segment acquired a major share in 2021. Hypertension is a common condition that is present in the human population. Hypertension can also result in cardiac arrest and even death. The rising incidences of hypertension is the primary reason for the large segmental share in the propranolol market. For instance, according to the World Health Organization, an estimated 1.28 billion adults aged 30-79 worldwide have hypertension, most (two-thirds) of whom live in lower-middle-income countries.
• Based on the type, the market is segmented into oral and intravenous. The intravenous segment is expected to grow with a higher CAGR in the propranolol drug market during the forecast period. Intravenous propranolol has several advantages. It provides a more rapid onset of action, allowing for more immediate control of blood pressure and heart rate in emergency situations which is an important factor for the fast growth of the segment.
• Based on distribution channels, the market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. As per our analysis, the hospital pharmacies segment acquired a major share in 2021. This is mainly due to the easily available medicines by the hospital pharmacies during any emergency situation. Further, hospital pharmacies are available inside the healthcare institution which is an important factor for the accessibility of the pharmacy during treatment is also an important factor driving the growth of hospital pharmacies.
• For a better understanding of the market adoption of the industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North American region held the dominant share of the propranolol drug market in 2021. In North America, propranolol is available by prescription and is marketed under various brand names, including Inderal and Hemangeol. The higher prescription rate in the region is one of the main reasons for the dominant market share of propranolol drugs. For instance, 8470628 were the estimated number of prescriptions of propranolol in the United States in 2020.
• Some of the major players operating in the market include Pierre Fabre Group; Hikma Pharmaceuticals PLC; Viatris Inc; GSK plc; Baxter; Teva Pharmaceutical Industries Ltd.; ANI Pharmaceuticals, Inc.; Amneal Pharmaceuticals LLC; Fresenius Kabi AG; and Par Pharmaceutical.